<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><description>姓药的来说药，带你进入最深层次的医药领域，把握医药动态，了解最新前沿！</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 15 Feb 2021 07:56:46 +0800</pubDate><image><url>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</url><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>肿瘤代谢重编程与免疫应答</title><link>https://mp.weixin.qq.com/s/bi-z_wkuANin3IQRnHAcTQ</link><description></description><content:encoded><![CDATA[肿瘤代谢重编程与免疫应答]]></content:encoded><pubDate>Mon, 15 Feb 2021 06:58:26 +0800</pubDate></item><item><title>B7-H3靶向抗体的肿瘤免疫治疗</title><link>https://mp.weixin.qq.com/s/0kA9GywSLZQ78Uh_Rmm1DQ</link><description></description><content:encoded><![CDATA[B7-H3靶向抗体的肿瘤免疫治疗]]></content:encoded><pubDate>Sat, 13 Feb 2021 08:07:46 +0800</pubDate></item><item><title>I/O全新策略！三级淋巴组织构筑的肿瘤免疫微环境</title><link>https://mp.weixin.qq.com/s/cbUbj7Op_AMlqwh1zofo-g</link><description></description><content:encoded><![CDATA[I/O全新策略！三级淋巴组织构筑的肿瘤免疫微环境]]></content:encoded><pubDate>Wed, 10 Feb 2021 08:05:53 +0800</pubDate></item><item><title>骨髓来源抑制细胞的新特征及靶向治疗应用</title><link>https://mp.weixin.qq.com/s/t119YlkZNK0_82my33eX4Q</link><description></description><content:encoded><![CDATA[骨髓来源抑制细胞的新特征及靶向治疗应用]]></content:encoded><pubDate>Sun, 07 Feb 2021 06:05:25 +0800</pubDate></item><item><title>IL-36：炎症与肿瘤</title><link>https://mp.weixin.qq.com/s/5C-ARsrYmj-FlPVL0uLMSA</link><description></description><content:encoded><![CDATA[IL-36：炎症与肿瘤]]></content:encoded><pubDate>Thu, 04 Feb 2021 10:23:17 +0800</pubDate></item><item><title>CD33靶向双特异性抗体的开发现状</title><link>https://mp.weixin.qq.com/s/3-YGrKyCuCfWj4EghgUaVA</link><description></description><content:encoded><![CDATA[CD33靶向双特异性抗体的开发现状]]></content:encoded><pubDate>Mon, 01 Feb 2021 06:00:46 +0800</pubDate></item><item><title>抗SARS-CoV-2中和抗体的临床进展</title><link>https://mp.weixin.qq.com/s/E2nU4_JCqWT-1B9RU2XgPw</link><description></description><content:encoded><![CDATA[抗SARS-CoV-2中和抗体的临床进展]]></content:encoded><pubDate>Fri, 29 Jan 2021 05:58:32 +0800</pubDate></item><item><title>IL-2和IL-15的肿瘤免疫中的调节作用及其应用前景</title><link>https://mp.weixin.qq.com/s/-ClKHlzksg4gmKxOlpCl3w</link><description></description><content:encoded><![CDATA[IL-2和IL-15的肿瘤免疫中的调节作用及其应用前景]]></content:encoded><pubDate>Mon, 25 Jan 2021 06:03:44 +0800</pubDate></item><item><title>阿斯利康PD-1/CTLA-4双抗，增强对PD-1+活化T细胞CTLA-4的阻断作用</title><link>https://mp.weixin.qq.com/s/3-R40BwBpwWnxayCI_VeIA</link><description></description><content:encoded><![CDATA[阿斯利康PD-1/CTLA-4双抗，增强对PD-1+活化T细胞CTLA-4的阻断作用]]></content:encoded><pubDate>Fri, 22 Jan 2021 06:24:29 +0800</pubDate></item><item><title>抗体药物的免疫原性</title><link>https://mp.weixin.qq.com/s/7Nk-fjXTh5kb9LVHqSmfTQ</link><description></description><content:encoded><![CDATA[抗体药物的免疫原性]]></content:encoded><pubDate>Mon, 18 Jan 2021 06:32:01 +0800</pubDate></item></channel></rss>